A reversibly cross-linked nanogel of immunomodulators that are tethered to cells and where the nanogel slowly degrades and releases the immunomodulator for autocrine stimulation.
A substance which induces an immune response in the body.
A fusion protein of a targeting ligand towards a receptor on an immune cell that is linked to an immunomodulator, whereby the fusion protein can be tethered to the surface of immune cells for paracrine and autocrine stimulation.
A lipid-based nanoformulation of encapsulated small molecule immunomodulators that is then tethered to specific immune cells and released from the immune cell to induce paracrine stimulation.
A T (or B) cell with a unique nucleotide sequence for its surface expressed receptor that arises during the gene rearrangement process for that receptor.
A procedure that detects and quantifies T cells that are specific for a given antigen within a biological sample.
Curative Immune System
The power of the immune system to cure disease; within our bodies, it continuously deploys more therapies than all of the world pharmaceutical companies in combination.
Designer Immune Medicines
A therapy that targets multiple antigens in the context of patient-specific HLA alleles, that enlist optimized T cell clonotypes, and that is armed with immunomodulators to overcome tolerizing mechanisms within an inhospitable environment, thereby empowering capabilities to eliminate an acute insult and to provide functional memory that augments the Immune Security Status.
Also known as an antigenic determinant, is the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells.
Human leukocyte antigen
The unique combination of peptide sequence, HLA allele and TCR sequence that dictate the antigen-specific recognition and response of a T cell clonotype.
A substance or component derived from, that enlists, or is elicited by the immune system to protect the body from possibly harm and mediated via specific recognition and response to an antigen.
A set of procedures that characterizes the composition and functional state of a population of clonotypes over time and/or as a response to a treatment.
Immune Security System:
The interface between an antigen-presenting cell or target cell and a lymphocyte such as a T, B or Natural Killer (NK) cell.
A natural or synthetic agent that activates, enhances, suppresses or restores immune function.
A set of procedures that characterize a range of innate and adaptive immune cell phenotypes and functions, including cell surface markers and/or soluble mediators (e.g., cytokines and chemokines), that shape the outcome of the immune response. Immune Security Status: the ability of the immune cells to combat infection and malignancy while avoiding damage to healthy tissues or autoimmunity.
A chimeric receptor comprised of the extracelluar domains of a pMHC and the intracellular portions of a TCR.
Mammalian epitope display.
An Immune Medicine that targets a series of antigens.
Generation of multiple clonotypes that target single or multiple antigens through recognition of specific epitopes to impart desired functions.
PRIME™ T cells
Repertoire Immune Medicine’s proprietary Prime Repertoire Immune Encoded T cells, which are a multi-antigen-targeted natural T cells for use in adoptive cell transfer. PRIME T cells are natural, multiclonal CD8 and CD4 cells featuring an optimized phenotype and high antigen-specific reactivity to multiple tumor antigens. PRIME T cells can be combined with tethered immunomodulators to make designer immunotherapies that target multiple antigens and provide T cell support and tumor microenvironment remodeling to enhance immune function.
A short sequence of amino acids PRIME™.
The sum of the unique receptors carried by T cells and B cells that compose a patient’s adaptive immune system.
The Repertoire Immune Medicine’s manufacturing platform that expands a T cell product from a patient to PRIMETM T-cell product. The STREAM biomanufacturing platform uses a proprietary dendritic cell priming technology to naturally expand a patients own tumor reactive T cells in an HLA independent manner. High process yields and the ability to freeze the resulting drug product enable repeat dosing for continued immune therapy, while automation and Single Use technologies support rapid, on-demand manufacturing. To enable the rapid deployment of novel immune coded therapies to patients, the STREAM platform features a modular production system that accelerates new products into the clinic.
Single cell sequencing
Sequence information from individual cells with optimized next-generation sequencing (NGS) technologies, providing a higher resolution of cellular differences and a better understanding of the function of an individual cell in the context of its microenvironment.
Repertoire Immune Medicines’ proprietary Primed Repertoire Immune Encoded T cells, which are a multi-antigen-targeted natural T cells for use in adoptive cell transfer.
The site in the body at which an Immune Medicine exerts its action. TCR: T cell receptor
Tethered Immune Modulator
A cytokine or small molecule immunomodulator that is associated with the cell either on the surface or within.
Macromolecules comprised of 4 identical pMHC molecules and further bound to a unique molecular identifier (UMI).
A major histocompatibility complex (MHC) molecule loaded with a peptide.